Intermethod differences in results for total PSA, free PSA, and percentage of free PSA

American Journal of Clinical Pathology

Volumn 129, Issue 6, 2008, Pages 952-958

  Slev, Patricia R ^a   La'ulu, Sonia L ^b   Roberts, William L ^a,c  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^c ARUP LABORATORIES   (United States)

Author keywords

Free PSA; Method comparison; Prostate specific antigen; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; AUTOANALYSIS; BLOOD; CLINICAL CHEMISTRY; COMPARATIVE STUDY; METHODOLOGY; REPRODUCIBILITY; STANDARD;

AUTOANALYSIS; CHEMISTRY, CLINICAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 45949106975     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/JYBPMFNUF6EYY9TB     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Hoffman RM. Viewpoint: limiting prostate cancer screening. Ann Intern Med. 2006;144:438-440.
3. Smith R, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2004. CA Cancer J Clin. 2004;54:41-52.
4. Svetec D, Thompson IM. PSA screening: current controversy. Ann Oncol. 1998;9:1283-1288.
5. Catalona WJ. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152:2037-2042.
6. Crawford ED, Leewansangtong S, Goktas S, et al. Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/mL and age specific reference range as a cutoff for abnormal values. Prostate. 1999;38:296-302.
7. Luboldt HJ, Bex A, Swoboda A, et al. Early detection of prostate cancer in Germany: study using digital rectal examination and 4.0 ng/mL prostate-specific antigen as a cutoff. Eur Urol. 2001;39:131-137.
8. Okegawa T, Kinjo M, Ohta M, et al. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL. Int J Urol. 2003;10:201-206.
9. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350:2239-2246.
10. Catalona WJ, Loeb S, Han M. Viewpoint: expanding prostate cancer screening. Ann Intern Med. 2006;144:441-443.
11. Gann PH, Ma J, Catalona WJ, et al. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol. 2002;167:2427-2434.
12. Tanguay S, Begin LR. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology. 2002;59:261-265.
13. Pepe P, Panella P, Savoca F, et al. Prevalence and clinical significance of prostate cancer among 12,682 men with normal digital rectal examination, low PSA levels (≤4 ng/mL) and percent free PSA cutoff values of 15 and 20%. Urol Int. 2007;78:308-312.
14. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542-1547.
15. Rafferty B, Rigsby P, Rose M, et al. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem. 2000;46:1310-1317.
16. Roddam AW, Rimmer J, Nickerson C, et al. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem. 2006;43:35-48.
17. Kort S, Martens F, Vanpoucke H, et al. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem. 2006;52:1568-1574.
18. Stephan C, Klaas M, Muller C, et al. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem. 2006;52:59-64.
19. Stephan C, Kramer J, Meyer HA, et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU Int. 2007;99:1427-1431.
20. Roddam AW, Price CP, Allen NE, et al. Assessing the clinical impact of prostate-specific antigen variability and nonequimolarity: a simulation study based on the population of the United Kingdom. Clin Chem. 2004;50:1012-1016.
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
22. VITROS Immunodiagnostics Products PSA, version 3.0, 2005-03 [package insert]. Rochester, NY: Ortho-Clinical Diagnostics; 2005.
23. ADVIA Centaur PSA, revision K, 2007-04 [package insert]. Tarrytown, NY: Bayer Healthcare; 2007.
24. ADVIA Centaur cPSA, revision H, 2007-04 [package insert]. Tarrytown, NY: Bayer Healthcare; 2007.